Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
03 August 2020 - 9:00PM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that it will report its second quarter financial results
after the close of the U.S. financial markets on Thursday, August
6, 2020. Nabriva’s management will host a conference call at 4:30
p.m. ET to discuss the financial results and recent corporate
highlights.
The dial-in number for the conference call is 866-811-8671 for
domestic participants and 409-981-0874 for international
participants, with Conference ID #4007639. A live webcast of
the conference call can be accessed through the “Investors” tab on
the Nabriva Therapeutics website at www.nabriva.com. A replay
will be available on this website shortly after conclusion of the
event for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections. Nabriva Therapeutics received
U.S. Food and Drug Administration approval for XENLETA® (lefamulin
injection, lefamulin tablets), the first systemic pleuromutilin
antibiotic for community-acquired bacterial pneumonia (CABP).
Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for
injection, a potential first-in-class epoxide antibiotic for
complicated urinary tract infections (cUTI), including acute
pyelonephritis.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva Therapeutics, including but not
limited to statements about Nabriva Therapeutics’ ability to
successfully launch and commercialize XENLETA for the treatment of
CABP or CAP, including the availability of and ease of access to
XENLETA in Europe and through major U.S. specialty distributors,
marketing exclusivity and patent protection for XENLETA, the
development of CONTEPO for cUTI, the clinical utility of XENLETA
for CABP and of CONTEPO for cUTI, plans for and timing of the
review of regulatory filings for CONTEPO, efforts to bring CONTEPO
to market, the market opportunity for and the potential market
acceptance of XENLETA for CABP or CAP and CONTEPO for cUTI, the
development of XENLETA and CONTEPO for additional indications, the
development of additional formulations of XENLETA and CONTEPO,
plans to pursue research and development of other product
candidates, the sufficiency of Nabriva Therapeutics’ existing cash
resources and its expectations regarding anticipated revenues from
product sales and how far into the future its existing cash
resources will fund its ongoing operations and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “likely,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: Nabriva Therapeutics’ ability to
successfully implement its commercialization plans for XENLETA and
whether market demand for XENLETA is consistent with its
expectations, Nabriva Therapeutics’ ability to build and maintain a
sales force for XENLETA, the content and timing of decisions made
by the European Commission, the U.S. Food and Drug Administration
and other regulatory authorities, the uncertainties inherent in the
initiation and conduct of clinical trials, availability and timing
of data from clinical trials, whether results of early clinical
trials or studies in different disease indications will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of CONTEPO for the treatment of cUTI, the
ability to retain and hire key personnel, the availability of
adequate additional financing on acceptable terms or at all and
such other important factors as are set forth in Nabriva
Therapeutics’ annual and quarterly reports and other filings on
file with the U.S. Securities and Exchange Commission. In addition,
the forward-looking statements included in this press release
represent Nabriva Therapeutics’ views as of the date of this press
release. Nabriva Therapeutics anticipates that subsequent events
and developments will cause its views to change. However, while
Nabriva Therapeutics may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Nabriva Therapeutics’ views as
of any date subsequent to the date of this press release.
CONTACTS:
For InvestorsGary SenderNabriva Therapeutics
plcir@nabriva.com
For MediaMike BeyerSam Brown
Inc.mikebeyer@sambrown.com312-961-2502
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2024 to May 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From May 2023 to May 2024